Legal Disclaimer
You are responsible for reading, understanding and agreeing to the National Law Review s (NLR’s) and the National Law Forum LLC s Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only. Any legal analysis, legislative updates or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys or other professionals or organizations who include content on the National Law Review website. If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor.
The
Clinical Oncology Next Generation Sequencing Market report helps to build the strategic plan by finding an intricate match between strategy and operation, strategic positioning of new product and services which depends on doing many things well, it showcases the understanding of the management cycle that links the strategy and operation and tells what tools to apply at each stage of the cycle, along with component of a management system which includes the integrated set of process and tools that a company uses to develop its strategy, translate it into operational action, and monitor and improve the efficacy of both.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global clinical oncology next generation sequencing market is expected to grow from $0.44 billion in 2020 to $0.56 billion in 2021 at a compound annual growth rate (CAGR) of 27.3%.
Major players in the clinical oncology next generation sequencing market are Thermo Fisher Scientific (Qiagen), Oxford Nanopore Technologies, QIAGEN, Myriad Genetics, Illumina, F. Hoffmann-La Roche, Perkin Elmer, Agilent Technologies, Pacific Bioscience, and Caris Life Sciences.
The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.05 billion in 2025 at a CAGR of 17%.
Metagenomics Market is expected to reach US$ 314.3 Mn by 2027 from US$ 165.8 in 2018 and estimated to grow with a CAGR of 7.7% from 2018-2027
iCrowd Newswire
05 May 2021, 11:07 GMT+10
According to The Insight Partners market research study titled Metagenomics Market to 2027 - Global Analysis and Forecasts by Product, Application, and Geography. The global metagenomics market is expected to reach US$ 314.3 Mn in 2027 from US$ 165.8 in 2018. The market is estimated to grow with a CAGR of 7.7% from 2018-2027. The report highlights the trends prevalent in the global metagenomics market and the factors driving the market along with those that act as deterrents to its growth.
Is Pacific Biosciences of California (PACB) A Good Investment Choice?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.58% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Health Care benchmarks that delivered a 6.17% and 2.14% returns respectively for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Baron Health Care Fund, in their Q1 2021 investor letter, mentioned Pacific Biosciences of California, Inc. (NASDAQ: PACB), and shared their insights on the company. Pacific Biosciences of California, Inc. is a Menlo Park, California-based biotechnology company that currently has a $6.2 billion market capitalization. Since the beginning of the year, PACB delivered a 25.56% return, impressively extending its 12-month gains to 885.48%. As of April 28,